Clinical Trial Update: A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating whether daily dosing with enzalutamide alters the metabolism of caffeine and dextromethorphan in men with prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Pharmacokinetics of Dextromethorphan, Pharmacokinetics of Caffeine | Phase 1 | Status: COMPLETED